1,7 per_100_person_yearsIn patients with pre-ART CD4 cell count 200–349 cells/μL, incidence of mortality was 1.7 per 100 person-years.
Côte d'IvoireVIH/sidapublié 2007AIDS (London, England)europe_pmcdocument de 9 observations
Palier Gold : evidences validées mécaniquement, avec leur source primaire.
709 evidences · page 4 / 29
1,7 per_100_person_yearsIn patients with pre-ART CD4 cell count 200–349 cells/μL, incidence of mortality was 1.7 per 100 person-years.
Côte d'IvoireVIH/sidapublié 2007AIDS (London, England)europe_pmcdocument de 9 observations
85,7 %Of the 312 patients initially classified as HIV-2, 267 (85.7%) were confirmed as HIV-2.
Côte d'IvoireVIH/sidaobservé 2012publié 2014Journal of the International AIDS Societyeurope_pmcdocument de 8 observations
100 000 copies/mLBaseline HIV-1 RNA <100 000 copies/mL was associated with virologic success.
Côte d'IvoireVIH/sidaobservé baselinepublié 2022Open Forum Infectious Diseaseseurope_pmcdocument de 4 observationsDOI 10.1093/ofid/ofac628
30 deathsIn the Temprano ANRS 12136 trial posttrial phase, 30 deaths occurred among HIV-infected West African adults who were randomized to defer antiretroviral therapy.
Côte d'IvoireVIH/sidapublié 2021Journal of acquired immune deficiency syndromes (1999)europe_pmcdocument de 6 observations
4 %The Senegal haplotype was detected in 4% of samples.
Côte d'Ivoirehemoglobinobservé 2022HAL · Unilimdocument de 23 observations
5,2 per_100_person_yearsAmong 1825 HIV-2-infected individuals initiating antiretroviral therapy, the mortality rate was 5.2 per 100 person-years of observation over the first 24 months.
Côte d'IvoireVIH/sidapublié 2016AIDS (London, England)europe_pmcdocument de 6 observations
4,7 log10 copies/mlThe median pre-antiretroviral treatment HIV-1 RNA level was 4.7 log10 copies per milliliter among 1013 patients in the Temprano trial conducted in Côte d'Ivoire.
Côte d'IvoireVIH/sidapublié 2022BMC infectious diseaseseurope_pmcdocument de 3 observationsDOI 10.1186/s12879-022-07082-2
0 %Plasmodium malariae accounted for 0.00% of identified Plasmodium species among 2246 positive blood smears.
Côte d'IvoirepaludismeHAL · Unilimdocument de 122 observations
73,33 %La fréquence de la neuropathie sensitive, sensitivo-motrice, polyneuropathique, démyélinisante, axonale et axono-démyélinisante chez les personnes diabétiques en Côte d'Ivoire était de 73,33 % en 2004.
Côte d'Ivoirediabète (non précisé) · neuropathie axonale · neuropathie axono-démyélinisante · neuropathie démyélinisante · neuropathie périphériqueobservé 2004HAL · Unilimdocument de 747 observations
34,3 %A seropositivity to HIV1 and/or HIV2 was observed in 72 (34.3%) of 210 female prostitutes in Ivory Coast from January to December 1987.
Côte d'IvoireHIV1 and/or HIV2observé 1987publié 1989PubMedOpenAlexdocument de 10 observations
351 individualsA total of 351 HIV-2-infected individuals participated in this study.
Côte d'IvoireVIH/sidaobservé 2012publié 2015PloS oneeurope_pmcdocument de 9 observations
35,3 %A seropositivity to HIV1 and/or HIV2 was observed in 23 (35.3%) of 65 patients with sexual transmitted diseases in Ivory Coast from January to December 1987.
Côte d'IvoireHIV1 and/or HIV2observé 1987publié 1989PubMedOpenAlexdocument de 10 observations
Symptomatic malaria case prevalence was the highest in Karafine (KAR).
Côte d'IvoirepaludismeHAL · Unilimdocument de 122 observations
19,3 %After 24 months of follow-up, 6 out of 31 patients (19.3%) died.
Côte d'Ivoireméningite cryptococciquepublié 2025IJID regionseurope_pmcdocument de 11 observations
4,5 per_100_person-yearsHIV incidence among regular male blood donors in Abidjan decreased from 4.5 per 100 person-years in 1992–1994 to 0.06 per 100 person-years in 2010–2012.
Côte d'IvoireVIH/sidaobservé 1992–1994publié 2018Open forum infectious diseaseseurope_pmcdocument de 12 observations
9,1 %HPV vaccination uptake among adolescents girls living with HIV (AGLHIV) in Côte d'Ivoire was 9.1% for those attending HIV care facilities located in Abidjan and 20.4% for those attending facilities outside Abidjan in the COVADOCY study conducted in 2025.
Côte d'Ivoireinfection à HPVobservé 2025HAL · Unilimdocument de 69 observations
32,2 %Of 457 participants included in this study, 147 (32.2%) had a positive urinary LAM.
Côte d'Ivoiretuberculosepublié 2025BMC infectious diseaseseurope_pmcdocument de 9 observations
4,3 %HCV prevalence was 4.3% among HIV-1-infected patients in the IeDEA HIV-2 West Africa cohort surveyed from March to December 2012.
Côte d'Ivoirehépatite C · VIH/sidaobservé March to December 2012publié 2018Journal of public health in Africaeurope_pmcdocument de 9 observations
10,8 %Among individuals aged 13–21 years and older, malaria prevalence was 10.8%.
Côte d'IvoirepaludismeHAL · Unilimdocument de 122 observations
The highest malaria case rates were recorded at the end of the rainy season (November–December 2016).
Côte d'Ivoirepaludismeobservé November–December 2016HAL · Unilimdocument de 122 observations
14,7 %Among 659 AGLHIV in Côte d'Ivoire participating in the COVADOCI study, 97 (14.7%) had received at least one HPV vaccine dose.
Côte d'Ivoireinfection à HPVHAL · Unilimdocument de 69 observations
The treatment has been unsuccessful.
Côte d'Ivoirevisceral leishmaniasispublié 2008Bulletin de la Societe de pathologie exotique (1990)europe_pmcdocument de 4 observations
21,3 %Occult HBV infection prevalence was 21.3% among HBsAg-negative, anti-HBcAb-positive, anti-HBsAb-negative patients with detectable HBV DNA.
Côte d'Ivoirehépatite B · VIH/sidaobservé 2006publié 2012World journal of hepatologyeurope_pmcdocument de 13 observations
5,2 %Among 344 HIV-infected pregnant women who conceived on antiretroviral therapy, the overall proportion of miscarriage was 5.2%.
Côte d'IvoireVIH/sidaobservé 2003–2009publié 2011Journal of acquired immune deficiency syndromes (1999)europe_pmcdocument de 9 observationsDOI 10.1097/qai.0b013e3181ff04e6
24,6 %Of 422 HIV-2-infected patients, 104 (24.6%) were treated with an unboosted PI-based regimen.
Côte d'IvoireVIH/sidapublié 2016Journal of the International AIDS Societyeurope_pmcdocument de 6 observations
Chaque ligne mène à son document source. Le nombre indiqué est celui des observations VALIDÉES qu'il porte, jamais celui des observations extraites : les deux diffèrent sur la plupart des documents. L'extrait exact du texte source n'est pas publié, par contrainte de droit d'auteur.